To biologically validate NeoSplice predicted splice variant neoantigens, a set of N neoantigen peptides predicted in the K562.A2 cell line (an AML cell line engineered to express HLA-A*02:01) were synthesized. This evidence concerns the gene HLA-A and acute myeloid leukemia.